Experienced in Multiple Myeloma

Malgorzata Kruszelnicka-Sobczyk

Gliwice Branch, 
Gliwice, SL, PL 
Experienced in Multiple Myeloma
Gliwice Branch, 
Gliwice, SL, PL 
OverviewLocationsClinical Research

Overview

Malgorzata Kruszelnicka-Sobczyk practices in Gliwice, Poland. Ms. Kruszelnicka-Sobczyk is rated as an Experienced expert by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Graft Versus Host Disease (GvHD), Cytomegalic Inclusion Disease, Multiple Myeloma, Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Multiple Myeloma.

Gender
Female

Locations

Gliwice Branch, Gliwice, SL 44102, Poland
Other Locations
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch
Gliwice, SL, Poland
Gliwice Branch, Gliwice, SL, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

38 Total Publications

miR-302d-3p expression and genotype are associated with CMV replication after allogeneic haematopoietic stem cell transplantation.
miR-302d-3p expression and genotype are associated with CMV replication after allogeneic haematopoietic stem cell transplantation.
Journal: Human immunology
Published: May 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kruszelnicka-Sobczyk's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile